Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase

Blood

Volumn 100, Issue 5, 2002, Pages 1910-1912

  List, Alan F ^a,b   Kopecky, Kenneth J ^a   Willman, Cheryl L ^a   Head, David R ^a   Slovak, Marilyn L ^a   Douer, Dan ^a   Dakhil, Shaker R ^a   Appelbaum, Frederick R ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P;

ADULT; AGED; ARTICLE; BLAST CELL; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0036721378     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.5.1910.h81702001910_1910_1912     Document Type: Article

References (31)

1. The biology of chronic myeloid leukemia
2. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor
3. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
4. The molecular biology of chronic myeloid leukemia
5. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway
6. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
7. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
8. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL
9. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
10. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
11. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance
12. Identification of members of the P-glycoprotein multigene family
13. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine
14. Overexpression of the mdr 1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A
15. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A
16. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance
17. MDR1 gene expression and treatment outcome in acute myeloid leukemia
18. Clinical significance of multidrug resistance P-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis
19. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype
20. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group Study
21. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study
22. P-glycoprotein in acute non-lymphoblastic leukemia and in the blastic crisis of myeloid leukemia
23. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukemia cells in blast crisis
24. Expression of mdr 1 and mdr 3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine
25. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
26. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
27. Efficacy of STI71, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
28. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
29. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase Inhibitor SCH66336
30. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein
31. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation and amplification